BriaCell Therapeutics Presents Positive Clinical Data For Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor And Further Analysis Of Phase 2 Data At ASCO Annual Meeting May 29 - June 2

Benzinga Newsdesk www.benzinga.com Positive 91.3%

Neg 0% Neu 0% Pos 91.3%

Comments

No comments yet. Be the first!